Works matching IS 03407004 AND DT 2023 AND VI 72 AND IP 5
Results: 23
Correction to: TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction to: Let‑7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL‑13 and IL‑10.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1315, doi. 10.1007/s00262-022-03336-9
- By:
- Publication type:
- Article
Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1301, doi. 10.1007/s00262-022-03335-w
- By:
- Publication type:
- Article
Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1285, doi. 10.1007/s00262-022-03334-x
- By:
- Publication type:
- Article
Senescence-associated secretory proteins induced in lung adenocarcinoma by extended treatment with dexamethasone enhance migration and activation of lymphocytes.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1273, doi. 10.1007/s00262-022-03332-z
- By:
- Publication type:
- Article
Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1261, doi. 10.1007/s00262-022-03330-1
- By:
- Publication type:
- Article
Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1247, doi. 10.1007/s00262-022-03329-8
- By:
- Publication type:
- Article
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1061, doi. 10.1007/s00262-022-03328-9
- By:
- Publication type:
- Article
Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1327, doi. 10.1007/s00262-022-03327-w
- By:
- Publication type:
- Article
Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1199, doi. 10.1007/s00262-022-03326-x
- By:
- Publication type:
- Article
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1233, doi. 10.1007/s00262-022-03322-1
- By:
- Publication type:
- Article
Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1185, doi. 10.1007/s00262-022-03321-2
- By:
- Publication type:
- Article
Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1225, doi. 10.1007/s00262-022-03320-3
- By:
- Publication type:
- Article
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1139, doi. 10.1007/s00262-022-03319-w
- By:
- Publication type:
- Article
Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1169, doi. 10.1007/s00262-022-03318-x
- By:
- Publication type:
- Article
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1153, doi. 10.1007/s00262-022-03317-y
- By:
- Publication type:
- Article
Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1121, doi. 10.1007/s00262-022-03316-z
- By:
- Publication type:
- Article
Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1103, doi. 10.1007/s00262-022-03315-0
- By:
- Publication type:
- Article
Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1089, doi. 10.1007/s00262-022-03313-2
- By:
- Publication type:
- Article
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1209, doi. 10.1007/s00262-022-03312-3
- By:
- Publication type:
- Article
Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1075, doi. 10.1007/s00262-022-03311-4
- By:
- Publication type:
- Article